We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure

By LabMedica International staff writers
Posted on 02 Aug 2023
Print article
Image: Monitoring of changes in longitudinal urine patterns can help predict heart failure (credit: R.Sakaniwa at el., European Journal of Heart Failure, 2023)
Image: Monitoring of changes in longitudinal urine patterns can help predict heart failure (credit: R.Sakaniwa at el., European Journal of Heart Failure, 2023)

Heart failure, a condition that will affect one in five individuals during their lifetime, is significantly associated with kidney impairments. As such, monitoring kidney health indicators in individuals susceptible to heart failure is standard practice. While short-term fluctuations in renal biomarkers are well-established, the link between long-term biomarker patterns and heart failure risk is yet to be understood. Now, researchers have discovered a key treatment target that could potentially prevent patients from developing serious heart conditions in the future.

In a new study, an international research team led by Osaka University (Suita, Japan) has successfully identified long-term trends in kidney health indicators among healthy European adults, and how these patterns influence the risk of new-onset heart failure. The research involved the examination of two prevalent kidney health markers—urinary albumin excretion (UAE) and serum creatinine—in nearly 7000 participants from the Dutch study Prevention of Renal and Vascular End-stage Diseases (PREVEND). The team monitored the trends in UAE and serum creatinine levels over an 11-year period, investigating their correlation with new-onset heart failure and death.

The study clearly revealed that the majority of participants exhibited stable low UAE or serum creatinine levels, but those with consistently high UAE were at a significantly increased risk of new-onset heart failure or all-cause mortality. Interestingly, annual levels of renal biomarkers remained notably stable year after year throughout the 11-year follow-up period. Stable serum creatinine levels over time correlated with heart failure, but not with an elevated risk of death. A more in-depth analysis revealed that individuals with consistently higher UAE or serum creatinine levels were more likely to be older, male, and to have conditions like diabetes, previous heart attack, or dyslipidemia. The study implies that reducing UAE could help decrease the risk of future heart failure and death in these patients. Given that heart failure is likely to affect one in five people during their lifetime, these findings could significantly influence preventive medicine and further validation of these results is required in non-European populations.

“Our results highlight the importance of the heart-kidney link in heart failure by showing that patients with persistently worse renal function, as indicated by higher UAE or serum creatinine levels, are at a higher risk of heart failure or mortality,” said Dr. Ryoto Sakaniwa, lead author of the study. “Reducing these renal biomarkers could help prevent heart failure.”

Related Links:
Osaka University

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
77 ELEKTRONIKA

Channels

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.